FFA
ARCT icon

Frazier Financial Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Frazier Financial Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4
Closed -$43 – 613
2025
Q1 		$43 Hold
4
– – ﹤0.01% 587
2024
Q4 		$67 Hold
4
– – ﹤0.01% 625
2024
Q3 		$93 Hold
4
– – ﹤0.01% 809
2024
Q2 		$98 Hold
4
– – ﹤0.01% 939
2024
Q1 		$136 Buy
+4
New +$142 ﹤0.01% 881

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Frazier Financial Advisors's ARCT Position: Q2 2025 in Review

Frazier Financial Advisors sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 4 shares — an estimated $43 sold.

Frazier Financial Advisors first reported a position in ARCT in Q1 2024 and held it in 5 quarters. The position peaked at $136 in Q1 2024. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Frazier Financial Advisors reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Frazier Financial Advisors sold 4 Arcturus Therapeutics shares in Q2 2025, an estimated $43.
  • Frazier Financial Advisors first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 5 quarters.
  • Frazier Financial Advisors's Arcturus Therapeutics position peaked at $136 in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Frazier Financial Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.